Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.34 Insider Own38.77% Shs Outstand32.43M Perf Week5.19%
Market Cap9.28M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float28.57M Perf Month51.64%
Income-12.17M PEG- EPS next Q- Inst Own26.18% Short Float18.08% Perf Quarter29.47%
Sales0.00M P/S- EPS this Y- Inst Trans-23.04% Short Ratio0.52 Perf Half Y-60.24%
Book/sh-0.27 P/B- EPS next Y- ROA-218.86% Short Interest5.17M Perf Year-77.91%
Cash/sh0.02 P/C10.31 EPS next 5Y- ROE- 52W Range0.11 - 1.21 Perf YTD-66.30%
Dividend Est.- P/FCF- EPS past 5Y7.15% ROI- 52W High-83.50% Beta-0.53
Dividend TTM- Quick Ratio0.23 Sales past 5Y0.00% Gross Margin- 52W Low78.78% ATR (14)0.04
Dividend Ex-Date- Current Ratio0.23 EPS Y/Y TTM59.43% Oper. Margin0.00% RSI (14)54.24 Volatility11.58% 22.99%
Employees4 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price4.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q52.24% Payout- Rel Volume0.10 Prev Close0.20
Sales Surprise- EPS Surprise0.00% Sales Q/Q- Earnings- Avg Volume9.98M Price0.20
SMA207.94% SMA5022.85% SMA200-47.54% Trades Volume1,021,631 Change-3.02%
Jun-28-24 09:00AM
Jun-27-24 08:00AM
Jun-25-24 08:30AM
Jun-20-24 09:47AM
07:28AM Loading…
Jun-18-24 07:54AM
Jun-11-24 08:30AM
May-28-24 08:00AM
May-24-24 05:00PM
Apr-19-24 05:00PM
Mar-22-24 04:30PM
Mar-20-24 01:40PM
08:00AM Loading…
Mar-14-24 08:00AM
Mar-11-24 07:00AM
Feb-23-24 07:30AM
Jan-12-24 04:30PM
Dec-29-23 04:30PM
Dec-04-23 09:06AM
Dec-01-23 07:30AM
Nov-28-23 07:30AM
Nov-27-23 08:30AM
Nov-16-23 08:00AM
Oct-25-23 04:30PM
Oct-19-23 05:00PM
Oct-12-23 09:40AM
Aug-28-23 07:30AM
07:00AM Loading…
Jul-03-23 07:00AM
Jun-30-23 04:05PM
Jun-19-23 07:30AM
Jun-15-23 08:30AM
Jun-14-23 07:30AM
May-08-23 08:30AM
May-04-23 08:30AM
May-02-23 08:45AM
Apr-25-23 08:50AM
Mar-27-23 08:30AM
Mar-01-23 08:30AM
Jan-30-23 08:30AM
Jan-25-23 08:30AM
Jan-23-23 08:30AM
Jan-12-23 08:30AM
Jan-11-23 08:30AM
Jan-10-23 08:30AM
Dec-22-22 08:30AM
Dec-20-22 09:05AM
Dec-14-22 08:30AM
Dec-07-22 08:25AM
Dec-01-22 08:00AM
Nov-23-22 08:30AM
Nov-14-22 08:30AM
Nov-07-22 08:45AM
Nov-02-22 10:40AM
Oct-05-22 04:30PM
Oct-03-22 08:30AM
Sep-27-22 12:02PM
Sep-19-22 08:00AM
Sep-08-22 08:00AM
Jul-28-22 08:30AM
Jul-21-22 08:30AM
Jun-10-22 04:30PM
Jun-06-22 08:30AM
Jun-02-22 08:30AM
May-04-22 09:00AM
Apr-26-22 06:45PM
Apr-22-22 12:00PM
Apr-13-22 08:30AM
Apr-01-22 05:25PM
Mar-31-22 08:15AM
Mar-28-22 08:30AM
Mar-25-22 08:30AM
Mar-16-22 01:49PM
Feb-25-22 09:30AM
Feb-11-22 08:30AM
Feb-07-22 08:46AM
Jan-12-22 08:15AM
Jan-04-22 08:15AM
Nov-30-21 08:30AM
Nov-01-21 08:15AM
Oct-20-21 08:48AM
Oct-14-21 08:30AM
Oct-04-21 04:30PM
Sep-30-21 11:55AM
Sep-28-21 08:30AM
Sep-24-21 08:15AM
Sep-14-21 08:30AM
Sep-08-21 08:00AM
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.